Journal of Bone and Joint Infection (Feb 2024)
Potential value of a rapid syndromic multiplex PCR for the diagnosis of native and prosthetic joint infections: a real-world evidence study
- S. Pascual,
- B. Noble,
- N. Ahmad-Saeed,
- C. Aldridge,
- S. Ambretti,
- S. Amit,
- R. Annett,
- S. A. O'Shea,
- A. M. Barbui,
- G. Barlow,
- L. Barrett,
- M. Berth,
- A. Bondi,
- N. Boran,
- S. E. Boyd,
- C. Chaves,
- M. Clauss,
- P. Davies,
- I. T. Dianzo-Delgado,
- J. Esteban,
- S. Fuchs,
- L. Friis-Hansen,
- D. Goldenberger,
- A. Kraševac Glaser,
- J. O. Groonroos,
- I. Hoffmann,
- T. Hoffmann,
- H. Hughes,
- M. Ivanova,
- P. Jezek,
- G. Jones,
- Z. Ceren Karahan,
- C. Lass-Flörl,
- F. Laurent,
- L. Leach,
- M. L. Horsbøll Pedersen,
- C. Loiez,
- M. Lynch,
- R. J. Maloney,
- M. Marsh,
- O. Milburn,
- S. Mitchell,
- L. S. P. Moore,
- L. Moffat,
- M. Murdjeva,
- M. E. Murphy,
- D. Nayar,
- G. Nigrisoli,
- F. O'Sullivan,
- B. Öz,
- T. Peach,
- C. Petridou,
- M. Prinz,
- M. Rak,
- N. Reidy,
- G. M. Rossolini,
- A.-L. Roux,
- P. Ruiz-Garbajosa,
- K. Saeed,
- L. Salar-Vidal,
- C. Salas Venero,
- M. Selvaratnam,
- E. Senneville,
- P. Starzengruber,
- B. Talbot,
- V. Taylor,
- R. Trebše,
- D. Wearmouth,
- B. Willinger,
- M. Wouthuyzen-Bakker,
- B. Couturier,
- F. Allantaz
Affiliations
- S. Pascual
- bioMérieux, Marcy l'Etoile, France
- B. Noble
- bioMérieux, Salt Lake City, USA
- N. Ahmad-Saeed
- University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
- C. Aldridge
- Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
- S. Ambretti
- S. Orsola Bologna, Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- S. Amit
- Sheba Medical Center, Ramat Gan, Israel
- R. Annett
- University Hospital of Wales, Cardiff, Wales, United Kingdom
- S. A. O'Shea
- University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
- A. M. Barbui
- San Giovanni Battista, Department of Public Health and Pediatrics Microbiology and Virology Unit, Città della Salute e della Scienza, Turin, Italy
- G. Barlow
- Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom
- L. Barrett
- Oxford University Hospitals (OUH), Oxford, United Kingdom
- M. Berth
- AZ Alma, Eeklo, Belgium
- A. Bondi
- Department of Public Health and Pediatrics, University of Turin, Turin, Italy
- N. Boran
- Mater Misericordiae University Hospital, Dublin, Ireland
- S. E. Boyd
- Chelsea and Westminster NHS Foundation Trust, London, United Kingdom
- C. Chaves
- Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- M. Clauss
- University Hospital Basel, Basel, Switzerland
- P. Davies
- NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, University of Glasgow, Glasgow, United Kingdom
- I. T. Dianzo-Delgado
- Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
- J. Esteban
- Dept. of Clinical Microbiology, IIS-Fundación Jiménez Díaz, CIBERINFEC-CIBER de Enfermedades Infecciosas, Madrid, Spain
- S. Fuchs
- Institute of Hygiene and Medical Microbiology Medizinische Universität Innsbruck, Innsbruck, Austria
- L. Friis-Hansen
- Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark; Dept. Clinical Microbiology at Rigshospitalet, Copenhagen, Denmark
- D. Goldenberger
- University Hospital Basel, Basel, Switzerland
- A. Kraševac Glaser
- NZOLH Maribor, Maribor, Slovenia
- J. O. Groonroos
- Varsinais-Suomen sairaanhoitopiiri, Loimaa, Finland
- I. Hoffmann
- MVZ Labor Dr. Reising-Ackermann und Kollegen, Limbach Leipzig, Germany
- T. Hoffmann
- Sheba Medical Center, Ramat Gan, Israel
- H. Hughes
- University Hospital of Wales, Cardiff, Wales, United Kingdom
- M. Ivanova
- East Tallinn Central Hospital, Tallin, Estonia
- P. Jezek
- Regional Hospital Příbram, Příbram, Czech Republic
- G. Jones
- University Hospital of Wales, Cardiff, Wales, United Kingdom
- Z. Ceren Karahan
- Ankara University School of Medicine Department of Medical Microbiology, Ankara, Türkiye
- C. Lass-Flörl
- Institute of Hygiene and Medical Microbiology Medizinische Universität Innsbruck, Innsbruck, Austria
- F. Laurent
- Hospices Civils de Lyon, Lyon, France
- L. Leach
- Oxford University Hospitals (OUH), Oxford, United Kingdom
- M. L. Horsbøll Pedersen
- Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark; Dept. Clinical Microbiology at Rigshospitalet, Copenhagen, Denmark
- C. Loiez
- Centre Hospitalier Universitaire de Lille, Lille, France
- M. Lynch
- Mater Misericordiae University Hospital, Dublin, Ireland
- R. J. Maloney
- Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom
- M. Marsh
- Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
- O. Milburn
- Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
- S. Mitchell
- University Hospital of Wales, Cardiff, Wales, United Kingdom
- L. S. P. Moore
- Chelsea and Westminster NHS Foundation Trust, London, United Kingdom
- L. Moffat
- NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, University of Glasgow, Glasgow, United Kingdom
- M. Murdjeva
- University Hospital “St George”, Plovdiv, Bulgaria
- M. E. Murphy
- NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, University of Glasgow, Glasgow, United Kingdom
- D. Nayar
- Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
- G. Nigrisoli
- S. Orsola Bologna, Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- F. O'Sullivan
- Mater Misericordiae University Hospital, Dublin, Ireland
- B. Öz
- Ankara University School of Medicine Department of Medical Microbiology, Ankara, Türkiye
- T. Peach
- University Hospital of Wales, Cardiff, Wales, United Kingdom
- C. Petridou
- Hampshire Hospitals NHS Foundation Trust, Winchester, UK
- M. Prinz
- Krankenhaus Göttlicher Heiland, Vienna, Austria
- M. Rak
- Koper lab, Orthopedic Hospital Valdoltra, Valdoltra, Slovenia
- N. Reidy
- Mater Misericordiae University Hospital, Dublin, Ireland
- G. M. Rossolini
- Careggi University Hospital, Florence, Italy
- A.-L. Roux
- Hôpital Ambroise Paré, APHP, Boulogne-Billancourt, France
- P. Ruiz-Garbajosa
- CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III. Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
- K. Saeed
- University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
- L. Salar-Vidal
- Dept. of Clinical Microbiology, IIS-Fundación Jiménez Díaz, CIBERINFEC-CIBER de Enfermedades Infecciosas, Madrid, Spain
- C. Salas Venero
- Hospital Universitario Marqués de Valdecilla, Santander, Spain
- M. Selvaratnam
- Oxford University Hospitals (OUH), Oxford, United Kingdom
- E. Senneville
- Centre Hospitalier Universitaire de Lille, Lille, France
- P. Starzengruber
- Allgemeines Krankenhaus Wien, Vienna, Austria
- B. Talbot
- NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, University of Glasgow, Glasgow, United Kingdom
- V. Taylor
- University Hospital of Wales, Cardiff, Wales, United Kingdom
- R. Trebše
- Koper lab, Orthopedic Hospital Valdoltra, Valdoltra, Slovenia
- D. Wearmouth
- Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom
- B. Willinger
- Allgemeines Krankenhaus Wien, Vienna, Austria
- M. Wouthuyzen-Bakker
- University Medical Center Groningen, Groningen, the Netherlands
- B. Couturier
- bioMérieux, Salt Lake City, USA
- F. Allantaz
- bioMérieux, Marcy l'Etoile, France
- DOI
- https://doi.org/10.5194/jbji-9-87-2024
- Journal volume & issue
-
Vol. 9
pp. 87 – 97
Abstract
Introduction: The BIOFIRE Joint Infection (JI) Panel is a diagnostic tool that uses multiplex-PCR testing to detect microorganisms in synovial fluid specimens from patients suspected of having septic arthritis (SA) on native joints or prosthetic joint infections (PJIs). Methods: A study was conducted across 34 clinical sites in 19 European and Middle Eastern countries from March 2021 to June 2022 to assess the effectiveness of the BIOFIRE JI Panel. Results: A total of 1527 samples were collected from patients suspected of SA or PJI, with an overall agreement of 88.4 % and 85 % respectively between the JI Panel and synovial fluid cultures (SFCs). The JI Panel detected more positive samples and microorganisms than SFC, with a notable difference on Staphylococcus aureus, Streptococcus species, Enterococcus faecalis, Kingella kingae, Neisseria gonorrhoeae, and anaerobic bacteria. The study found that the BIOFIRE JI Panel has a high utility in the real-world clinical setting for suspected SA and PJI, providing diagnostic results in approximately 1 h. The user experience was positive, implying a potential benefit of rapidity of results' turnover in optimising patient management strategies. Conclusion: The study suggests that the BIOFIRE JI Panel could potentially optimise patient management and antimicrobial therapy, thus highlighting its importance in the clinical setting.
